Literature DB >> 7857384

Micronised fenofibrate.

A Munoz, J P Guichard, P Reginault.   

Abstract

Rationale and development of a new fenofibrate formulation is described. A lower dispersion of particles size and thereby a better absorption rate leads to a decrease of the daily dose and provides a better control of the amount absorbed. Improved reproducibility of the pharmacological and therapeutic effect is expected.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7857384     DOI： 10.1016/0021-9150(94)05375-s

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


  19 in total

1.  Differences in reference products: dissolution and in vivo evidence.

Authors:  I J McGilveray
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

2.  A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations.

Authors:  Matthew F Crum; Natalie L Trevaskis; Hywel D Williams; Colin W Pouton; Christopher J H Porter
Journal:  Pharm Res       Date:  2015-12-24       Impact factor: 4.200

3.  The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule.

Authors:  Hwi-Yeol Yun; Eun Joo Lee; Soo Youn Chung; Sun-Ok Choi; Hyung Kee Kim; Jun-Tack Kwon; Wonku Kang; Kwang-Il Kwon
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.

Authors:  J C Adkins; D Faulds
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Authors:  D B Miller; J D Spence
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

7.  Manufacturing nanosized fenofibrate by salt assisted milling.

Authors:  Vadym N Mochalin; Adarsh Sagar; Shruti Gour; Yury Gogotsi
Journal:  Pharm Res       Date:  2009-02-18       Impact factor: 4.200

8.  Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations.

Authors:  Hywel D Williams; Philip Sassene; Karen Kleberg; Marilyn Calderone; Annabel Igonin; Eduardo Jule; Jan Vertommen; Ross Blundell; Hassan Benameur; Anette Müllertz; Colin W Pouton; Christopher J H Porter
Journal:  Pharm Res       Date:  2013-05-10       Impact factor: 4.200

Review 9.  Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

Authors:  Gillian M Keating; Douglas Ormrod
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Impact of Mixing on Content Uniformity of Thin Polymer Films Containing Drug Micro-Doses.

Authors:  Guluzar G Buyukgoz; Jeremiah N Castro; Andrew E Atalla; John G Pentangelo; Siddharth Tripathi; Rajesh N Davé
Journal:  Pharmaceutics       Date:  2021-05-29       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.